Immunome, Inc.
IMNM
$18.27
-$0.12-0.65%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -63.29% | -23.23% | -4.44% | 16.74% | -13.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -63.29% | -23.23% | -4.44% | 16.74% | -13.76% |
| Cost of Revenue | 23.67% | 36.86% | 91.05% | 180.45% | 337.24% |
| Gross Profit | -30.46% | -41.36% | -102.97% | -217.91% | -540.87% |
| SG&A Expenses | 22.28% | 32.81% | 37.89% | 60.26% | 65.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.39% | 36.04% | 77.72% | 143.81% | 229.38% |
| Operating Income | -28.73% | -39.53% | -85.17% | -162.70% | -298.52% |
| Income Before Tax | -9.50% | 27.50% | 27.05% | 19.12% | 11.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.50% | 27.50% | 27.05% | 19.12% | 11.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.50% | 27.50% | 27.05% | 19.12% | 11.60% |
| EBIT | -28.73% | -39.53% | -85.17% | -162.70% | -298.52% |
| EBITDA | -28.81% | -39.34% | -85.22% | -163.31% | -298.63% |
| EPS Basic | 25.81% | 53.37% | 51.28% | 45.30% | 41.94% |
| Normalized Basic EPS | 10.85% | 1.81% | -41.05% | -72.46% | -77.41% |
| EPS Diluted | 25.89% | 53.40% | 51.22% | 45.24% | 41.88% |
| Normalized Diluted EPS | 10.85% | 1.81% | -41.05% | -72.46% | -77.41% |
| Average Basic Shares Outstanding | 45.98% | 48.94% | 47.90% | 73.88% | 120.99% |
| Average Diluted Shares Outstanding | 45.98% | 48.94% | 47.90% | 73.88% | 120.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |